Extended therapy with [ < sup > 177 < /sup > Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer

CONCLUSION: Extended radioligand therapy is a feasible treatment option in patients with high-volume residual tumor after the completion of standard treatment with six cycles of [177Lu]Lu-PSMA-617. Improved survival and the acceptable safety profile warrant further investigation of the concept of additional cycles in selected patients.PMID:36702927 | DOI:10.1007/s00259-023-06119-1
Source: Molecular Medicine - Category: Molecular Biology Authors: Source Type: research